Canada's Bausch Health beats Q1 adjusted EPS estimates

Bausch Health Companies

29/04/2026 21:29

Overview

Canada pharmaceutical firm's Q1 revenue rose 12% yr/yr, organic growth 7%

Adjusted EPS for Q1 beat analyst expectations

Company reaffirmed full-year 2026 revenue, adjusted EBITDA, and cash flow guidance

Outlook

Company sees 2026 revenue of $10.67 bln to $10.92 bln, up 2%-5% vs prior yr

Company expects 2026 adjusted EBITDA of $3.89 bln to $4.01 bln, up 3%-5%

Company says evolving tariffs and trade measures create ongoing uncertainty for 2026 outlook

Result Drivers

SALIX SEGMENT - Growth driven by Xifaxan, which posted 21% revenue growth in Q1

SOLTA MEDICAL - Segment revenue rose 51%, aided by acquisition of Shibos aesthetics business in China and growth in APAC, especially China and South Korea

GOODWILL IMPAIRMENT - Net loss driven by $1.43 bln goodwill impairment charge related to Salix's RED-C program

Company press release: ID:nCNW6RNqka

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Adjusted EPS
Beat
$0.78
$0.69 (4 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

The stock recently traded at 1 times the next 12-month earnings vs. a P/E of 2 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)